LO-021 Interim safety and efficacy of subcutaneous (s.c.) dose ianalumab (VAY736; anti-BAFF-R mAb) administered monthly over 28 weeks in patients with systemic lupus erythematosus... by Yuko Kaneko, Masato Okada, Stephanie Finzel, Nan Shen, Elena Vishneva, Lingyun Sun, Bernadette Rojkovich, Alberta Hoi, Shin-Seok Lee, Piotr Leszczyński, Lie Dai, Rafal Wojciechowski, Cheng-Chung Wei, Katarzyna Romanowska-Prochnicka, Hiroshi Kaneko, Stanislav Ignatenko, Alexander Gordienko, Josefina Hernandez, Nancy Levin, Pongthorn Narongroeknawin, Hanna Ciferska, Masanari Kodera, Joung Liang Lan, Tunde Tarr, Yi Hsing Chen, Ajchara Koolvisoot, Eugeny Zotkin, Berta Paula magallares, Tirtha Sengupta, Carole Sips, Stephan Oliver